GenSight Biologics SA (0RIM) Stock Statistics & Valuation Metrics
Total Valuation
GenSight Biologics SA has a market cap or net worth of EUR 18.98M. The enterprise value is EUR 29.15M.
- Market Cap
- EUR 18.98M
- Enterprise Value
- EUR 29.15M
Share Statistics
GenSight Biologics SA has 246,217,330 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 246,217,330
- Owned by Insiders
- ―
- Owned by Institutions
- 0.10%
Financial Efficiency
GenSight Biologics SA’s return on equity (ROE) is 0.48 and return on invested capital (ROIC) is 1518.16%.
- Return on Equity (ROE)
- 0.48
- Return on Assets (ROA)
- -1.46
- Return on Invested Capital (ROIC)
- 1518.16%
- Return on Capital Employed (ROCE)
- 2.65
- Revenue Per Employee
- 55.556
- Profits Per Employee
- -668.67K
- Employee Count
- 18
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of GenSight Biologics SA is -1.06. GenSight Biologics SA’s PEG ratio is -0.02.
- PE Ratio
- -1.06
- PS Ratio
- -13.94
- PB Ratio
- -0.51
- Price to FCF
- -1.48
- Price to Operating Cash Flow
- -2.09
- PEG Ratio
- -0.02
Income Statement
In the last 12 months, GenSight Biologics SA had revenue of 1,000 and earned -12.04M in profits. Earnings per share was -0.08.
- Revenue
- 1,000
- Gross Profit
- 1,000
- Operating Income
- -11.71M
- Pretax Income
- -12.04M
- Net Income
- -12.04M
- EBITDA
- -11.24M
- Earnings Per Share (EPS)
- -0.08
Cash Flow
In the last 12 months, operating cash flow was -8.22M and capital expenditures 6.43M, giving a free cash flow of -8.50M billion.
- Operating Cash Flow
- -8.22M
- Free Cash Flow
- -8.50M
- Free Cash Flow per Share
- -0.04
Dividends & Yields
GenSight Biologics SA pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -67.57%
- Earnings Yield
- -89.07%
Stock Price Statistics
- Beta
- 0.47
- 52-Week Price Change
- -48.72%
- 50-Day Moving Average
- 0.10
- 200-Day Moving Average
- 0.09
- Relative Strength Index (RSI)
- 47.63
- Average Volume (3m)
- 94.61K
Important Dates
GenSight Biologics SA upcoming earnings date is Mar 19, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Sep 29, 2026
- Next Earnings Date
- Mar 19, 2027
- Ex-Dividend Date
- ―
Financial Position
GenSight Biologics SA as a current ratio of 0.39, with Debt / Equity ratio of -51.57%
- Current Ratio
- 0.39
- Quick Ratio
- 0.39
- Debt to Market Cap
- 0.81
- Net Debt to EBITDA
- -0.93
- Interest Coverage Ratio
- -11.86
Taxes
In the past 12 months, GenSight Biologics SA has paid 5,000 in taxes.
- Income Tax
- 5,000
- Effective Tax Rate
- -0.00
Enterprise Valuation
GenSight Biologics SA EV to EBITDA ratio is -1.80, with an EV/FCF ratio of -2.79.
- EV to Sales
- -26.30
- EV to EBITDA
- -1.80
- EV to Free Cash Flow
- -2.79
- EV to Operating Cash Flow
- -2.89
Balance Sheet
GenSight Biologics SA has EUR 1.67M in cash and marketable securities with EUR 12.84M in debt, giving a net cash position of -EUR 11.16M billion.
- Cash & Marketable Securities
- EUR 1.67M
- Total Debt
- EUR 12.84M
- Net Cash
- -EUR 11.16M
- Net Cash Per Share
- -EUR 0.05
- Tangible Book Value Per Share
- -EUR 0.15
Margins
Gross margin is 100.00%, with operating margin of 1526.14%, and net profit margin of 1698.78%.
- Gross Margin
- 100.00%
- Operating Margin
- 1526.14%
- Pretax Margin
- 1737.21%
- Net Profit Margin
- 1698.78%
- EBITDA Margin
- 1463.34%
- EBIT Margin
- 1526.14%
Analyst Forecast
The average price target for GenSight Biologics SA is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -610.31%
- EPS Growth Forecast
- 43.88%
